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A B S T R A C T
Background
Pulmonary embolism (PE) is a common life-threatening cardiovascular condition, with an incidence of 23 to 69 new cases per 100,000
people each year. For selected low-risk patients with acute PE, outpatient treatment might provide several advantages over traditional
inpatient treatment, such as reduction of hospitalisations, substantial cost savings, and improvements in health-related quality of life.
This is an update of the review first published in 2014.
Objectives
To compare the efficacy and safety of outpatient versus inpatient treatment in low-risk patients with acute PE for the outcomes of all-
cause and PE-related mortality; bleeding; adverse events such as haemodynamic instability; recurrence of PE; and patients’ satisfaction.
Search methods
The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase,
CINAHL and AMED databases, and the World Health Organization International Clinical Trials Registry Platform and ClinicalTri-
als.gov trials registers, to 26 March 2018. We also undertook reference checking to identify additional studies.
Selection criteria
We included randomised controlled trials of outpatient versus inpatient treatment of adults (aged 18 years and over) diagnosed with
low-risk acute PE.
Data collection and analysis
Two review authors selected relevant trials, assessed methodological quality, and extracted and analysed data. We calculated effect
estimates using risk ratio (RR) with 95% confidence intervals (CIs), or mean differences (MDs) with 95% CIs. We used standardised
mean differences (SMDs) to combine trials that measured the same outcome but used different methods. We assessed the quality of
the evidence using GRADE criteria.
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Main results
One new study was identified for this 2018 update, bringing the total number of included studies to two and the total number of
participants to 451. Both trials discharged patients randomised to the outpatient group within 36 hours of initial triage and both
followed participants for 90 days. One study compared the same treatment regimens in both outpatient and inpatient groups, and the
other study used different treatment regimes. There was no clear difference in treatment effect for the outcomes of short-termmortality
(30 days) (RR 0.33, 95% CI 0.01 to 7.98, P = 0.49; low-quality evidence), long-term mortality (90 days) (RR 0.98, 95% CI 0.06 to
15.58, P = 0.99, low-quality evidence), major bleeding at 14 days (RR 4.91, 95% CI 0.24 to 101.57, P = 0.30; low-quality evidence)
and at 90 days (RR 6.88, 95% CI 0.36 to 132.14, P = 0.20; low-quality evidence), minor bleeding (RR 1.08, 95% CI 0.07 to 16.79;
P = 0.96, low-quality evidence), recurrent PE within 90 days (RR 2.95, 95% CI 0.12 to 71.85, P = 0.51, low-quality evidence), and
participant satisfaction (RR 0.97, 95% CI 0.90 to 1.04, P = 0.39; moderate-quality evidence). We downgraded the quality of the
evidence because the CIs were wide and included treatment effects in both directions, the sample sizes and numbers of events were
small, and because the effect of missing data and the absence of publication bias could not be verified. PE-related mortality, and adverse
effects such as haemodynamic instability and compliance, were not assessed by the included studies.
Authors’ conclusions
Currently, only low-quality evidence is available from two published randomised controlled trials on outpatient versus inpatient
treatment in low-risk patients with acute PE. The studies did not provide evidence of any clear difference between the interventions in
overall mortality, bleeding and recurrence of PE.
P L A I N L A N G U A G E S U M M A R Y
Outpatient versus inpatient treatment for acute pulmonary embolism
Background
Pulmonary embolism (PE) is the third most common and life-threatening cardiovascular disease worldwide. There are between 23
and 69 new cases of PE per 100,000 people each year. For selected low-risk patients with acute (sudden-onset) PE, outpatient (home)
treatment might provide several advantages over traditional inpatient treatment, such as reduction of hospital admissions, substantial
cost savings, and improvements in health-related quality of life. This systematic review aimed to evaluate the risks and benefits of
outpatient versus inpatient treatment in low-risk patients with acute PE.
Study characteristics
We searched scientific databases for clinical trials of low-risk adults (aged 18 years and over) allocated to home (outpatient) management
or hospital (inpatient) management of acute PE. The evidence is current to March 2018.
Key results
We included two studies, which included a total of 453 people.We are uncertainwhether, comparedwith inpatient treatment, outpatient
treatment has an important effect on number of deaths, bleeding, recurrence of PE, and patient satisfaction because the results were
imprecise and the studies did not report side effects such as haemodynamic instability (where drugs or procedures are needed tomaintain
a stable blood pressure), and compliance (how well people follow medical advice).
Quality of the evidence
The evidence from the included studies was of low quality because of imprecision in the results. This was due to there being only small
numbers of people in the studies (and small numbers of events), and because we could not confirm the absence of publication bias
(reports of studies where no effect was shown might not be published). Therefore, further well-conducted randomised controlled trials
(where people are allocated at random to one of two or more treatment groups, one of which is a control treatment) are required before
informed practice decisions can be made.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Outpatient compared with inpatient treatment for acute pulmonary embolism
Patient or population: people with low-risk acute pulmonary embolism
Settings: outpat ient and inpat ient sett ings
Intervention: outpat ient sett ing1
Comparison: inpat ient sett ing2
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No. of participants
(RCTs)
Quality of the evidence
(GRADE)
Comments
risk with inpatient set-
ting
risk with outpatient
setting
Short- term all- cause
mortality
Follow-up: 7-10 days af -
ter randomisat ion
Study populat ion RR 0.33 (0.01 to 7.98) 453
(2)
⊕⊕©©
low3
1/ 168 deaths in the in-
pat ient group vs 0/ 171
deaths in the outpa-
t ient group. No deaths
occurred in Peacock
2018. No deaths re-
ported by Aujesky 2011
were PE-related.4 per 1000 1 per 1000 (0 to 35)
Long- term all- cause
mortality
Follow-up: 90 days af ter
randomisat ion
Study populat ion RR 0.98 (0.06 to 15.58) 4514
(2)
⊕⊕©©
low3
1/ 168 deaths in the in-
pat ient group vs 1/ 171
deaths in the outpa-
t ient group. No deaths
occurred in Peacock
2018. No deaths re-
ported by Aujesky 2011
were PE-related.4 per 1000 4 per 1000 (0 to 68)
Major bleeding
Follow-up: 14 days af ter
randomisat ion
Not est imable RR 4.91 (0.24 to 101.
57)
445
(2)
⊕⊕©©
low3
0/ 168 major bleeding
events in the inpat ient
group vs 2/ 171 ma-
jor bleeding events in
the outpat ient group.
3
O
u
tp
a
tie
n
t
v
e
rsu
s
in
p
a
tie
n
t
tre
a
tm
e
n
t
fo
r
a
c
u
te
p
u
lm
o
n
a
r
y
e
m
b
o
lism
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
9
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
No major bleeding oc-
curred in Peacock
2018.
Major bleeding
Follow-up: 90 days af ter
randomisat ion
Not est imable RR 6.88 (0.36 to 132.
14)
445
(2)
⊕⊕©©
low3
0/ 168 major bleeding
events in the inpat ient
group vs 3/ 171 ma-
jor bleeding events in
the outpat ient group.
No major bleeding oc-
curred in Peacock
2018.
Minor bleeding Study populat ion RR 1.08 (0.07 to 16.79) 106
(1)
⊕⊕©©
low3
One part icipant in each
treatment arm reported
minor bleeding18 per 1000 20 per 1000 (1 to 305)
Recurrent PE
Follow-up: within 90
days
Not est imable RR 2.95 (CI 0.12 to 71.
85)
445
(2)
⊕⊕©©
low3
0/ 168 recurrent PE in
inpat ient groups vs 1/
171 recurrent PE in the
outpat ient group, had
a recurrent PE within
90 days. No recurrent
PE occurred in Peacock
2018.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RCT: randomised controlled trial; RR: risk rat io; PE: pulmonary embolism
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
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1 Outpat ients received subcutaneous enoxaparin twice daily (Aujesky 2011); or rivaroxaban 15 mg orally twice daily for the
f irst 21 days, followed by 20 mg orally once daily for approximately 69 days, for a total treatment durat ion of 90 days
(Peacock 2018).
2 In Aujesky 2011, the inpat ient group was admitted to hospital and received subcutaneous enoxaparin 1 mg/ kg twice daily.
In Peacock 2018, the inpat ient group was admitted to hospital and received variable pharmacotherapy (standard-of -care
treatment).
3 We downgraded by two levels due to the overall small sample size, small number of events, imprecision in the conf idence
intervals and the fact that publicat ion bias could not be discounted.
4 Addit ional information was requested f rom the study authors but as they were unable to provide it , we used only the available
data.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Pulmonary embolism (PE) is a common life-threatening cardio-
vascular illness. It is a potentially fatal disease that, despite ade-
quate treatment, is still associated with high morbidity and mor-
tality; the reported incidence in the US exceeds one case per 1000
population and the 90-day all-cause mortality is as high as 9% to
15% after diagnosis (Goldhaber 1999; Laporte 2008). In 2005,
Heit and colleagues estimated that in the US each year there are
around 237,000 cases of non-fatal PE and 294,000 cases of fatal
PE (Heit 2005). In 2007, Cohen and colleagues reported that of
all people admitted to hospitals, 1% die of acute PE and about
10% of all in-hospital deaths are PE-related (Cohen 2007).
The diagnosis of PE has improved with advances in imaging tech-
nology, and the management of PE has changed with the intro-
duction of treatments such as non-vitamin K antagonist oral anti-
coagulants (NOACs). The mortality rate of PE has also changed.
In 2011, Pollack and colleagues reported a 5.4% all-cause mor-
tality rate across 22 medical centres in the US (Pollack 2011).
In the international Computerized Registry of Patients with Ve-
nous Thromboembolism (RIETE registry) of over 23,000 pa-
tients, Jiménez 2016 noted a 30-day all-cause mortality rate of
5.9%, and Vinson 2018 found a 30-day all-cause mortality rate
of a 4.4%, across 21 US medical centres.
The prognosis and treatment of people diagnosed with acute PE
are related to the initial haemodynamic status. High-risk PE (mas-
sive PE) - defined by the presence of shock or persistent arterial
hypotension (systolic blood pressure below 90 mmHg or systolic
blood pressure drop by 40 mmHg or more, for over 15 minutes,
if not caused by new-onset arrhythmia, hypovolaemia, or sepsis) -
accounts for 5% of all cases of PE and has a poor prognosis, with
a short-term mortality of more than 15% (Konstantinides 2014).
Conversely, in haemodynamically stable patients, non-high-risk
(low risk) PE (non-massive PE) accounts for 95% of all cases of
PE, and has significantly lower short-termmortality which ranges
between less than 1% and 15% (Buller 2003; Ibrahim 2008;
Konstantinides 2014; Quinlan 2004). The question is whether
people with low-risk PE should be treated as outpatients or inpa-
tients.
Description of the intervention
The traditional initial anticoagulant therapy in acute PE in hos-
pitals is administration of standardised intravenous unfraction-
ated heparin (UFH), subcutaneous lowmolecular weight heparins
(LMWH) or fondaparinux started together with oral vitamin K
antagonists (referred as the overlap treatment period) for at least
five days until the prothrombin time yields an international nor-
malised ratio (INR) above 2.0 for two consecutive days.
Since the 1990s, subcutaneous LMWH have largely replaced in-
travenous UFH therapy and have enabled outpatient therapy for
deep vein thrombosis (DVT) in many situations without labora-
tory anticoagulant monitoring (Othieno 2018). Although most
people with acute PE are hospitalised during initial therapy, it is
feasible that in selected low-risk people, outpatient care can safely
and effectively be used rather than inpatient care.
The non-vitamin K antagonist oral anticoagulants (NOACs),
known as factor Xa inhibitors (e.g. rivaroxaban, apixaban and
edoxaban) and direct thrombin inhibitors (e.g. dabigatran), are
available in many countries for the treatment of venous throm-
boembolism (VTE). In patients with PE who are haemodynami-
cally stable (PE without hypotension), the use of NOACs is effi-
cient and safe (Ghazvinian 2018). The tenth edition of the Amer-
ican College of Chest Physicians (ACCP) guidelines suggests that
initial parenteral anticoagulation is given before dabigatran and
edoxaban, while rivaroxaban and apixaban do not require initial
parenteral anticoagulation (Kearon 2016).
Studies comparing inpatient versus outpatient treatment of PE
have used early discharge as soon as patients achieve a clinically
stable condition (Aujesky 2011; Otero 2010). Treatment at home
of a substantial number of patients with low-risk acute PE (even
during the traditional period of overlap with heparin and vitamin
K antagonists) seems to be a feasible option.
Most cases of acute PE are managed within a hospital setting be-
cause of the uncertainty in safely identifying low-risk patients. In
addition, during management of acute PE, some patients require
intensive treatment in hospital due to potentially fatal complica-
tions such as clinical deterioration. Therefore, when considering
management in an outpatient setting it is important to identify
those patients who are considered as being at low risk of major
(fatal) complications.
Several risk assessment strategies, such as clinical scores, imaging
modalities and laboratory biomarkers, are available to identify pa-
tients who could be treated at home safely. The Agterof 2010 study
reported that patients with low N-terminal pro-brain natriuretic
peptide (NT-proBNP) levels (less than 500 pg/mL), and who are
haemodynamically stable, would be a safe group of patients to
receive care in an outpatient setting. Furthermore, Lankeit 2011
considered the troponin T (TnT) assay, along with simplified Pul-
monary Embolism Severity Index (sPESI), as a risk assessment tool
to identify patients with acute PE who could be treated at home
safely.
In addition, there are four scoring systems to select low-risk pa-
tients with acute PE for outpatient management: the Geneva pre-
diction score (GPS), the Pulmonary Embolism Severity Index
(PESI), the simplified version of the PESI (sPESI) andHestia crite-
ria (Aujesky 2005; den Exter 2016b; Jiménez 2010; Wicki 2000).
TheGPS was derived from 296 outpatients confirmed with symp-
tomatic acute PE and identifies six independent predictors (can-
cer, heart failure, previous DVT, systolic blood pressure less than
100 mmHg, partial pressure of oxygen dissolved in arterial blood
6Outpatient versus inpatient treatment for acute pulmonary embolism (Review)
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(PaO2) less than 8 kPa and presence of DVT on ultrasound exam)
of an adverse outcome (death, recurrent thromboembolic event or
major bleeding) in a three-month follow-up period (Wicki 2000,
see Appendix 1). The PESI criteria were derived from 15,531 in-
patients discharged with PE, which identified 11 factors indepen-
dently associated with 30-day mortality (age, male gender, cancer,
heart failure, chronic lung disease, pulse rate 110 beats/minutes
or greater, systolic blood pressure less than 100 mm Hg, respira-
tory rate 30 breaths/minute or greater, body temperature less than
36°C, altered mental status and oxyhaemoglobin saturation less
than 90%) (Aujesky 2005, see Appendix 2).
The sPESI was developed with six items that may be more useful
and practical for routine utilisation in emergency departments. It
was shown that the sPESI can predict 30-day mortality after acute
PE and that it has similar prognostic accuracy when compared to
the original PESI (Jiménez 2010, see Appendix 3).
The Hestia criteria were derived from a multicentre prospective
cohort study in 297 patients treated as outpatients among 581
patients with PE (Zondag 2011, see Appendix 4). The Hestia
criteria used 11 practical clinical exclusion rules to select patients
for outpatient treatment. Later on, these criteria were validated
in 550 patients by combining the cutoff NT-proBNP levels for
outpatient treatment as 500 ng/L (den Exter 2016b).
Jiménez and colleagues assessed the ability of two models (GPS
and PESI) in comparing and validating a distinct set of ambulatory
patients with acute symptomatic PE to identify low-risk patients
for anticoagulant therapy in the outpatient setting (Jiménez 2007).
In this study, the PESI quantified the prognosis of patients with
acute PE significantly better than the GPS. Hence, the PESI can
select and identify low-risk patients for adverse events within 30
days of anticoagulant therapy in acute PEwith very good accuracy.
Zondag and colleagues compared the performance of the sPESI
and the Hestia criteria in selecting low-risk patients for anticoagu-
lant therapy in the outpatient setting (Zondag 2013). This study
demonstrated that both the sPESI and theHestia criteria classified
different patients as being suitable for outpatient treatment and
suggests that when the Hestia criteria is applied it may identify a
proportion of patients considered as high risk by sPESI (such as
those with malignant diseases, cardiopulmonary comorbidities or
advanced age) to be treated at home.
Why it is important to do this review
The eighth edition of the ACCP guidelines discussed the feasi-
bility of outpatient treatment in acute PE among a substantial
proportion of patients, but provided no formal recommendations
(Kearon 2008). In the same way, the task force of the European
Society of Cardiology (ESC) did not clearly recommend early dis-
charge or outpatient management for acute PE in selected patients
(Konstantinides 2014). The ninth edition of the ACCP guidelines
suggested early discharge over standard discharge (e.g. after the
first five days of treatment) for patients with low-risk PE whose
home circumstances were adequate (Grade 2B) (Kearon 2012).
However, patients who preferred the security of the hospital to the
convenience and comfort of home were likely to choose hospital-
isation over home treatment.
The increasing availability of NOACs as a treatment of acute PE
allows management without the need for hospitalisation. Hence,
the tenth edition of the ACCP guidelines suggested home treat-
ment of acute PE, provided that patients fulfil the following con-
ditions: 1) clinically stable with good cardiopulmonary reserve; 2)
no contraindications such as recent haemorrhage, severe kidney
or liver disease, or severe thrombocytopenia (i.e. platelets less than
70,000/mm3); 3) expected to be compliant with treatment; and
4) the patient feels confident to be treated at home. However, in
patients with right ventricular dysfunction or increased cardiac
biomarker levels, out-of-hospital treatment is not recommended
(Kearon 2016).
The 2018 guideline from the British Thoracic Society proposes
similar recommendations (Howard 2018). Patients with con-
firmed PE should be risk-stratified using a validated clinical risk
score: patients in PESI class I/II, sPESI class 0, or those meeting
the Hestia criteria should be considered for outpatient manage-
ment of PE. Where PESI or sPESI is used and indicates a low risk,
a set of exclusion criteria should be considered for the outpatient
management of PE (Appendix 5).
Outpatient treatment instead of traditional inpatient treatment
in selected low-risk patients with acute PE can provide several
advantages, for example, a reduction innumber of hospitalisations,
a substantial cost saving and an improvement in health-related
quality of life (Dasta 2015; Fanikos 2013). It is therefore important
to establish whether, in clinically stable, low-risk acute PE patients,
outpatient treatment is at least as safe and effective as inpatient
treatment.
O B J E C T I V E S
To compare the efficacy and safety of outpatient versus inpatient
treatment in low-risk patients with acute PE for the outcomes of
all-cause and PE-related mortality; bleeding; and adverse events
such as haemodynamic instability, recurrence of PE and patients’
satisfaction.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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We included randomised controlled trials (RCTs) and quasi-RCTs
(in which allocation to treatment was obtained by alternation,
use of alternate medical records, date of birth or other predictable
methods) in this systematic review. We included quasi-RCTs as
we did not anticipate finding many RCTs in this area.
Types of participants
We included adults (18 years and older) diagnosed with low-risk
acute pulmonary embolism (PE), defined as acute onset of dysp-
noea or chest pain together with a new contrast-filling defect on
single- or multi-detector computed tomography (CT) pulmonary
angiography or pulmonary digital angiography, a new high-prob-
ability ventilation-perfusion lung scan or documentation of a new
proximal deep vein thrombosis (DVT) either by venous ultra-
sonography or contrast venography.
We considered people to be of low risk if they were classified
as low risk by any validated or non-validated measurement tool
that aimed to classify mortality risk rate related to PE, such as
the Geneva prediction score (GPS) , the Pulmonary Embolism
Severity Index (PESI), the simplified PESI (sPESI) or the Hestia
criteria.
Types of interventions
• Intervention group: participants allocated to home
(outpatient) management for acute PE.
• Control group: participants allocated to hospital (inpatient)
management for acute PE.
We considered outpatients as people who were discharged within
36 hours after the low-risk acute PE diagnosis and who then com-
pleted treatment at home (outpatient care).
Types of outcome measures
Primary outcomes
• Short-term all-cause mortality (from the date of
randomisation to 7 to 10 days).
• Long-term all-cause mortality (from the date of
randomisation to 90 days).
Long-term all-cause mortality at 90 days included any all-cause
mortality noted from the date of randomisation to 90 days. We
considered both all-cause mortality and PE-related mortality.
Secondary outcomes
• Bleeding (from the date of randomisation to 90 days): we
defined major bleeding as fatal or clinically overt bleeding
resulting in fall of haemoglobin by 2 g/L or more or bleeding
into critical anatomical sites (subdural haematoma, intraspinal
haemorrhage, retroperitoneal, intraocular, pericardial, atraumatic
intra-articular) or leading to transfusion of 2 U or more of blood
or red cells (Schulman 2005). We defined minor bleeding as
bleeding requiring intervention but not qualifying as a major
bleeding, including bleeding precipitating treatment cessation
(Schulman 2005).
• Adverse effects, such as haemodynamic instability (from the
date of randomisation to 90 days).
• Recurrence of PE (from the date of randomisation to 90
days).
• Participant satisfaction or compliance, or both (from the
date of randomisation to 90 days): we accepted methods used by
study investigators, including Likert scale questionnaires.
Search methods for identification of studies
Electronic searches
The Cochrane Vascular Information Specialist conducted system-
atic searches of the following databases for RCTs and controlled
clinical trials, with no restrictions on language, publication year
or publication status:
• the Cochrane Vascular Specialised Register via the Cochrane
Register of Studies (CRS-Web, searched on 28 March 2018);
• the Cochrane Central Register of Controlled Trials
(CENTRAL) Cochrane Register of Studies Online (2018, Issue
2);
• MEDLINE (Ovid MEDLINE® Epub Ahead of Print, In-
Process & Other Non-Indexed Citations, Ovid MEDLINE®
Daily and Ovid MEDLINE®) (searched from 1 January 2017 to
26 March 2018);
• Embase Ovid (searched from 1 January 2017 to 26 March
2018);
• CINAHL Ebsco (searched from 1 January 2017 to 26
March 2018);
• AMED Ovid (searched from 1 January 2017 to 28 March
2018).
The Information Specialist modelled search strategies for other
databases on the search strategy designed for CENTRAL. Where
appropriate, they were combined with adaptations of the highly
sensitive search strategy designed by Cochrane for identifying
RCTs and controlled clinical trials (as described in Chapter 6
of the Cochrane Handbook for Systematic Reviews of Interventions
Lefebvre 2011). Search strategies for major databases are provided
in Appendix 6.
The Information Specialist searched the following trials registries
on 28 March 2018:
• the World Health Organization International Clinical Trials
Registry Platform (who.int/trialsearch);
• ClinicalTrials.gov ( clinicaltrials.gov).
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Searching other resources
We checked the reference lists of the identified studies for addi-
tional citations.
Data collection and analysis
Selection of studies
Two review authors (HHBY, VSNN) independently screened the
trials identified by the literature search.We resolved disagreements
by consulting with the third review author (PJFVB) and consulted
with him regarding quality assurance of the processes.
Data extraction and management
Two review authors (HHBY, VSNN) independently extracted
data. We resolved any discrepancies by discussion. We used a stan-
dard data extraction form to extract the following information:
characteristics of the study (design, methods of randomisation),
participants, interventions and outcomes (types of outcome mea-
sures, adverse events). We then checked for accuracy before en-
tering the data in Review Manager 5 software (Review Manager
2014).
Assessment of risk of bias in included studies
We assessed study quality using Cochrane’s ’Risk of bias’ tool (
Higgins 2011). We used the following six criteria.
Random sequence generation
We recorded random sequence generation as ’low risk of bias’
where the method used was either adequate or unlikely to intro-
duce bias; as ’unclear risk of bias’ where therewas insufficient infor-
mation to assess whether the method used was likely to introduce
bias; or as ’high risk of bias’ when the method used (e.g. quasi-
randomised trials) was improper and likely to introduce bias.
Allocation concealment
We recorded allocation concealment as ’low risk of bias’ when the
method used (e.g. central allocation) was unlikely to introduce
bias in the final observed effect; as ’unclear risk of bias’ when there
was insufficient information to assess whether the method used
was likely to introduce bias in the estimate of effect; or as ’high
risk of bias’ when the method used (e.g. open random allocation
schedule) was likely to introduce bias in the final observed effect.
Blinding
For this clinical review, it is not possible to blind participants and
investigators for treatment allocation (i.e. inpatient and outpa-
tient), therefore we did not consider performance bias as part of
the ’Risk of bias’ assessment. We did consider blinding of outcome
measures. We recorded blinding of assessors as ’low risk of bias’ if
blinding was performed adequately, or the outcome measurement
was not likely to be influenced by lack of blinding; as ’unclear risk
of bias’ if there was insufficient information to assess whether the
type of blinding used was likely to introduce bias in the estimate
of effect; or ’high risk of bias’ if there was no blinding or incom-
plete blinding, and the outcome or the outcome measurement was
likely to be influenced by lack of blinding.
Incomplete outcome data
We recorded incomplete outcome data as ’low risk of bias’ when
the underlying reasons for missing data were unlikely to make
treatment effects depart from plausible values, or proper methods
were employed to handle missing data. In addition, we considered
a withdrawal rate less than 20% in each group to be ’low risk of
bias’. We recorded an ’unclear risk of bias’ when there was insuffi-
cient information to assess whether the missing data mechanism,
in combination with the method used to handle missing data, was
likely to introduce bias in the estimate of effect; and as ’high risk
of bias’ when the crude estimate of effects (e.g. complete-case esti-
mate) was clearly biased due to the underlying reasons for missing
data, and the methods used to handle missing data were unsatis-
factory.
Selective reporting
We recorded selective reporting as ’low risk of bias’ when the trial
protocol was available and all of the trial’s prespecified outcomes
that were of interest in the review were reported. We recorded
an ’unclear risk of bias’ when there was insufficient information
to assess whether the magnitude and direction of the observed
effect was related to selective outcome reporting; or as ’high risk
of bias’ when not all of the trial’s prespecified primary outcomes
were reported.
Other bias
We considered aspects of methodology that might have been in-
fluenced by vested interests and which may lead directly to a risk
of bias as ’Other bias’.
Two review authors (VSNN, PJFVB), independently made a
judgement as to whether the risk of bias for each criterion was
considered to be ’low’, ’unclear’ or ’high’. We resolved disagree-
ments by discussion. We considered trials that were classified as
’low risk of bias’ in sequence generation, allocation concealment,
blinding of outcome assessors, incomplete data and selective out-
come reporting as trials that were of overall low risk of bias.
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Measures of treatment effect
Binary outcomes
For dichotomous data, we used risk ratios (RRs) as the effect mea-
sure with 95% confidence intervals (CIs).
Continuous outcomes
For continuous data, we presented the results as mean differences
(MDs) with 95% CIs. When pooling data across studies, we esti-
mated the MDs if the outcomes were measured in the same way
between trials. We used standardised mean differences (SMDs) to
combine trials that measured the same outcome but used different
methods.
Unit of analysis issues
The unit of analysis was each participant recruited into the trials.
Dealing with missing data
An intention-to-treat (ITT) analysis is an analysis in which all
the participants in a trial are analysed according to the interven-
tion to which they were allocated, whether they received the in-
tervention or not. We assumed that participants who dropped out
were non-respondents. For each trial, we reported whether or not
the investigators stated if the analysis was performed according to
the ITT principle. If participants were excluded after allocation,
we reported any details provided in full. Furthermore, we per-
formed the analysis on an ITT basis whenever possible (Newell
1992). Otherwise, we adopted the ’available-case analysis’. Study
authors provided some further information on missing data when
requested.When this was not possible, we only used available data
in the analyses.
Assessment of heterogeneity
We looked for clinical heterogeneity by examination of the study
details and then tested for statistical heterogeneity between trial
results using the Chi2 test and the I2 statistic (Deeks 2011). As
recommended in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011), we considered size and direction of
effect and interpreted heterogeneity using the following I2 thresh-
olds for interpretation:
• 0% to 40%: might not be important;
• 30% to 60%: might represent moderate heterogeneity;
• 50% to 90%: might represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
We planned to assess the likelihood of potential publication bias
using funnel plots in addition to assessing the risk of selective
outcome reporting considered under assessment of risk of bias in
included studies. When small studies in a meta-analysis tend to
show larger treatment effects, we planned to consider other causes
including selection biases, poor methodological quality, hetero-
geneity and chance. However, the number of studies included in
the review prevented this.
Data synthesis
Weused the fixed-effectmodel to analyse data. If we identified sub-
stantial heterogeneity (e.g. I2 greater 50%), we planned to com-
pute pooled estimates of the treatment effect for each outcome
using a random-effects model (with two or more studies). We un-
dertook quantitative analysis of outcomes on an ITT basis.
Subgroup analysis and investigation of heterogeneity
In the case of substantial clinical heterogeneity (I2 greater than
50%), we planned to use subgroup analysis to explore the results.
We planned to perform the Chi2 test for subgroup differences,
set at a P value of 0.05. We planned to carry out analysis of the
following subgroups.
• Low molecular weight heparins (LMWH) (e.g. tinzaparin,
enoxaparin, dalteparin) and selective factor Xa inhibitors (e.g.
fondaparinux)
• Once-daily versus twice-daily administration of LMWH
and selective factor Xa inhibitors
• Outpatient discharge period (24 hours or less versus more
than 24 hours)
• Classification criteria (i.e. PESI versus GPS)
• Inpatients and outpatients with same treatment regimens
versus inpatients and outpatients treated with different treatment
regimens
Sensitivity analysis
If sufficient numbers of studies were identified for inclusion, we
planned to perform a sensitivity analysis to explore causes of het-
erogeneity and the robustness of the results.We planned to include
the following factors in the sensitivity analysis, separating studies
according to:
• trials with low risk of bias versus trials with high risk of bias;
• rates of withdrawal for each outcome (less than 20% versus
20% or greater).
As only two studies were included we were unable to do this.
’Summary of findings’ table
We used the principles of the GRADE system to assess the quality
of the body of evidence associated with specific primary outcomes
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(short- and long-term mortality), as well as secondary outcomes
(bleeding and recurrent PE), in our review and construct a ’Sum-
mary of findings’ table using the GRADE software (GRADEpro
GDT 2015; Guyatt 2008). The GRADE approach appraises the
quality of a body of evidence based on the extent to which one
can be confident that an estimate of effect or association reflects
the item being assessed. The assessment of the quality of a body
of evidence considers within-study risk of bias (methodological
quality), the directness of the evidence, heterogeneity of the data,
precision of effect estimates and risk of publication bias.
R E S U L T S
Description of studies
Results of the search
In this 2018 update of the review we identified one new study
which met the inclusion criteria (Peacock 2018), and excluded
two new studies (den Exter 2016; HOME Study). The HOME
Study was listed as an ongoing study in the previous version of
this review (Yoo 2014). See Figure 1.
11Outpatient versus inpatient treatment for acute pulmonary embolism (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram.
Included studies
One new additional study met our inclusion criteria for this 2018
update (Peacock 2018), bringing the total number of included
studies to two. Aujesky 2011 was included in the previous version
and involved 339 participants; Peacock 2018 randomised 114 par-
ticipants. See also Characteristics of included studies.
Study design
Both trials were described by the trialists as international, open-
label, randomised, non-inferiority trials (Aujesky 2011; Peacock
2018). They evaluated a period of three months. The studies dif-
fered both in terms of site of care and pharmacotherapy.
Types of interventions
12Outpatient versus inpatient treatment for acute pulmonary embolism (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Aujesky 2011 compared outpatient treatment (171 participants)
versus inpatient treatment (168 participants) of acute PE.
Participants assigned to outpatient treatment received subcuta-
neous enoxaparin 1 mg/kg twice daily and were to be discharged
from the emergency department (ED) within 24 hours of ran-
domisation. If self injection was not possible, a study nurse either
taught a caregiver to inject the enoxaparin or arranged adminis-
tration by a visiting nurse. Participants assigned to receive inpa-
tient treatment were admitted to hospital and received the same
enoxaparin regimen. All participants received vitamin K antago-
nist therapy.
In Peacock 2018, the outpatient group (51 participants) was dis-
charged home from the ED no later than 12 to 24 hours after
triage. They received 15 mg oral rivaroxaban twice daily for the
first 21 days, followed by 20 mg oral rivaroxaban once daily for
approximately 69 days, for a total treatment duration of 90 days.
The inpatient comparison group (63 participants) received local
standard-of-care, according to local protocol and defined by the
medical team caring for the participant, which typically involved
intravenous UFH or subcutaneous LMWH and hospitalisation,
but also included any of the NOACs. Seventy-five per cent of all
patients were initially treated with unfractionated or LMWH but
ultimately received NOACs, most commonly rivaroxaban (51%)
or apixaban (25%).
Types of outcomes measured
Aujesky 2011 considered the primary outcome of ’recurrence of
symptomatic venous thromboembolism’ measured by helical CT
or new perfusion defect involving 75% or more of a lung segment
by lung scan; or pulmonary angiography; or autopsy; or documen-
tation of a new proximal DVT either by venous ultrasonography
or contrast venography (Aujesky 2011).
As a safety measurement, the study assessed bleeding (evaluated
at 14 and 90 days) and death. Aujesky 2011 defined major bleed-
ing as fatal bleeding, bleeding at critical sites (i.e. intracranial, in-
traspinal, intraocular, retroperitoneal, intra-articular, pericardial
or intramuscular with compartment syndrome), or bleeding with
a reduction of haemoglobin of 20 g/L or more or resulting in
transfusion of two units or more of packed red cells.
Aujesky 2011 also assessed overall satisfaction 14 days after ran-
domisation using an non-validated five-point Likert scale ques-
tionnaire.
Peacock 2018 evaluated the primary outcomes of duration of ini-
tial and subsequent hospitalisations for bleeding or VTE events (or
both) within 30 days and 90 days of randomisation. The secondary
outcomes of interest were percentage of participants with reoccur-
rence of symptomatic venous thromboembolism event (VTE), or
VTE-related death (at 7, 14, 30, and 90 days), all-cause mortality
and serious adverse events, percentage of participants with number
of unplanned hospital visits or physician office for VTE symptoms
and/or bleeding (at 7, 14, 30 and 90 days), minor bleeding, mean
combined duration of initial and subsequent ED hospitalisation
for any reason up to 30 and 90 days. Patient satisfaction was eval-
uated at day seven, using five-point and three-point Likert scales,
with higher scores indicating greater satisfaction. Satisfaction was
further evaluated on day 90 with the Anti-Clot Treatment Score,
which uses two subscales of burdens (12 items) and benefits (three
items), both measured on a five-point Likert scale, with higher
scores indicating greater satisfaction.
Excluded studies
We excluded four published studies from the review: Kovacs 2003
was a randomised controlled clinical trial that evaluated different
doses of warfarin in outpatients; Zondag 2011 was classified as
cohort study; Otero 2010 evaluated three to five days in the hos-
pital as outpatients; and den Exter 2016 randomised patients to
either outpatient treatment or to management according toN-ter-
minal pro-brain natriuretic peptide (NT-pro BNP) levels.We also
excluded a study previously listed as an ongoing study, in which
patients were randomised to either Hestia or PESI management
(HOME Study). See Characteristics of excluded studies.
Risk of bias in included studies
See Figure 2 and Figure 3.
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Figure 2. Risk of bias summary: review authors’ judgments about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgments about each risk of bias item presented as
percentages across all included studies.
Allocation
We classified Aujesky 2011 as having low risk of selection bias
as it used a computer programme to generate the allocation to
treatment groups using randomised block design. We also clas-
sified Peacock 2018 as having low risk of selection bias because
participants were randomly assigned in a 1:1 ratio to discharge
or standard care by an interactive web system within 12 hours of
diagnosis.
Blinding
Since it is not possible to blind participants and investigators for
treatment allocation for this particular clinical question we did not
consider performance bias as part of the ’Risk of bias’ assessment.
InAujesky 2011, data analyserswere unmasked to treatment group
assignment.However, therewas a committee unaware of treatment
assignment which confirmed all outcomes and classified the cause
of all deaths as caused (or not) by PE, major bleeding, or due to
another cause. Therefore, we judged the study to be of low risk of
detection bias.
In Peacock 2018, analysers were masked to treatment group as-
signment, and so we considered the study to have a low risk of
bias.
Incomplete outcome data
Although both studies reported less than 20% of dropouts and
withdrawals - two from the outpatient group and five from the
inpatient group in Aujesky 2011, and seven from the outpatient
group and eight from the inpatient group in Peacock 2018 - we
classified both as having an unclear risk of attrition bias. In Peacock
2018, despite seven dropouts in the early discharged group, at
the end of the study, the study authors could confirm that all of
these participants were alive. However, for the inpatient group
they could not confirm this for two participants. In Aujesky 2011,
for individuals who did not complete the study, the study authors
were unable to confirm how many were alive.
Selective reporting
There was no evidence of selective reporting in either of the in-
cluded studies (Aujesky 2011; Peacock 2018).
Other potential sources of bias
There was no evidence of other potential sources of bias in the
included studies (Aujesky 2011; Peacock 2018). We considered
the imbalance between the two groups in Peacock 2018 as differ-
ent pharmacotherapy regimes were used in the arms. However, as
50% of the outpatient group received the same treatment as the
inpatient group, both studies were judged as being at low risk of
other bias.
Effects of interventions
See: Summary of findings for the main comparisonOutpatient
comparedwith inpatient treatment for acute pulmonary embolism
Outpatient versus inpatient treatment of acute
pulmonary embolism
We identified two trials comparing outpatient (222 participants)
and inpatient (231 participants) treatment of acute PE (Aujesky
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2011; Peacock 2018). The studies differed both in terms of site of
care and pharmacotherapy. In Aujesky 2011, both groups of par-
ticipants received subcutaneous enoxaparin 1 mg/kg twice every
day. In Peacock 2018, the outpatient group received rivaroxaban,
and the inpatient group received standard care (treatment based
on local institutional protocols, defined by the medical team car-
ing for the participant, which typically involved bridging therapy
and hospitalisation, but also included any of the NOACs). More
than 75% of inpatients ultimately received some type of direct-
acting oral anticoagulant, with 50.8% receiving rivaroxaban. To
investigate if the difference in treatment regimes influenced the
results, we have pooled the data from the studies using subgroup
analysis.
Primary outcomes
Short-term all-cause mortality (from the date of
randomisation to 7 to 10 days)
In Aujesky 2011, one death occurred on day 17 after the ran-
domisation in the inpatient group (1/168), due to pneumonia and
cancer, and there were no deaths in the outpatient group (0/171).
No deaths occurred in Peacock 2018. There was no clear effect of
intervention due to imprecision (risk ratio (RR) 0.33, 95% con-
fidence interval (CI) 0.01 to 7.98; 451 participants; two studies;
P = 0.49; low-quality evidence) (Analysis 1.1).
Long-term all-cause mortality (from the date of
randomisation to 90 days)
In Aujesky 2011, one death occurred on day 17 after the randomi-
sation in the inpatient group (1/168), due to pneumonia and can-
cer, and one death occurred on day 34 in the outpatient group (1/
171), due to trauma-related aortic rupture. No deaths occurred
in Peacock 2018. There was no clear effect of intervention due to
imprecision (RR 0.98, 95% CI 0.06 to 15.58; 451 participants;
two studies; P = 0.99; low-quality evidence) (Analysis 1.2).
Short-term pulmonary embolism-related mortality (from the
date of randomisation to 7 to 10 days)
No short-term PE-related deaths occurred in either study (Aujesky
2011; Peacock 2018).
Long-term pulmonary embolism-related mortality (from the
date of randomisation to 90 days)
No long-term PE-related deaths occurred in either study (Aujesky
2011; Peacock 2018).
Secondary outcomes
Bleeding
a. Major bleeding
In Aujesky 2011, two outpatients (2/171), and no inpatients (0/
168), had major bleeding within 14 days (one of the events was an
intramuscular haematoma on day three and one was by insertion
of vena cava filter on day 13). Peacock 2018 reported no major
bleeding by 90 days; we therefore assumed that no major bleeding
had occurred by 14 days. There was no clear effect of interven-
tion within 14 days due to imprecision (RR 4.91, 95% CI 0.24
to 101.57; 445 participants; two studies; P = 0.30; low-quality
evidence) (Analysis 1.3).
In Aujesky 2011, three outpatients (3/171), and no inpatients (0/
168), had major bleeding within 90 days. No major bleeding oc-
curred in Peacock 2018. There was no clear effect of intervention
within 90 days due to imprecision (RR 6.88, 95% CI 0.36 to
132.14; 445 participants; two studies; P = 0.20; low-quality evi-
dence) (Analysis 1.4.
b. Minor bleeding
Aujesky 2011 did not report on minor bleeding. In Peacock 2018
two participants reported International Society on Thrombosis
and Haemostasis (ISTH) clinically relevant non-major bleeding,
one from each randomisation group, which we considered as being
minor bleeding. There was no clear effect of intervention due to
imprecision (RR 1.08, 95% CI 0.07 to 16.79; 106 participants;
one study; P = 0.96, low-quality evidence) Analysis 1.5.
Adverse effects such as haemodynamic instability
The trials did not report on adverse effects such as haemodynamic
instability.
Recurrence of pulmonary embolism
In Aujesky 2011, one outpatient (1/171), and no inpatients (0/
168), had a recurrent PE within 90 days (long term). There were
no cases of recurrence of pulmonary embolism in Peacock 2018.
There was no clear difference between the treatment groups (RR
2.95, 95% CI 0.12 to 71.85; 445 participants; two studies; P =
0.51; low-quality evidence) (Analysis 1.6). There were no events
in either group regarding the short-term recurrence of PE (within
14 days analysis).
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Patient satisfaction or compliance, or both
In Aujesky 2011, 156 of 170 outpatients (92%) and 158 of 167
inpatients (95%) were very satisfied or satisfied with the medical
care received. In Peacock 2018, 29 of 48 outpatients (60%) and
37 of 59 inpatients (63%) were very satisfied with assignment to
intervention or control group. There was no clear evidence to sup-
port a difference between the two interventions regarding patient
satisfaction (RR 0.97, 95% CI 0.90 to 1.04, 444 participants; two
studies; P = 0.97). The quality of evidence was downgraded to
moderate because the effect of missing data and the absence of
publication bias could not be verified. The trials did not report on
compliance.
Other analyses
Due to a lack of included studies, we were unable to perform
sensitivity analyses and an analysis for publication bias. We had
intended to carry out subgroup analyses as described in Subgroup
analysis and investigation of heterogeneity. These were also limited
by the number of studies included, however, where possible, we
performed subgroup analysis according to treatment regimens. For
themajority of the outcomeswewere unable to check for subgroup
differences due to there being zero events in one or more studies.
Where data were sufficient, no subgroup differences were seen
in the satisfaction levels between treatment regimens (P = 0.97,
Analysis 1.7).
D I S C U S S I O N
Although non-vitamin K antagonist oral anticoagulants (NOACs)
have gained approval for the management of venous thromboem-
bolism (VTE), the effect of this on site-of-care decision making
has not yet been fully evaluated for outpatient management of PE
(Vinson 2018), with early research suggesting little impact (Kline
2016; Stein 2016). However, the advent of subcutaneous low
molecular weight heparins (LMWH), fondaparinux and NOACs
has rendered the possibility of expanding the traditional in-hospi-
tal treatment of acute pulmonary embolism (PE) to early discharge
or complete treatment in the outpatient setting (Kearon 2016).
Regardless, themagnitude of patients with acute PE receiving out-
patient treatment is still low in most industrialised countries (Roy
2017).
The potential benefits of home treatment of PE over traditional
hospital treatment include several factors: reduction of hospital-
isations, substantial cost saving, improvement in health-related
quality of life (Dasta 2015; Fanikos 2013), and increased physical
activity and social functioning. Nevertheless, one of the challenges
is how to identify patients considered as being at low risk of mor-
tality that can benefit from home management. For many years,
the lack of prognostic criteria to identify patients with a low risk of
mortality could not allow safe home management (Vinson 2012;
Zondag 2012).
In the Computerized Registry of Patients with Venous Throm-
boembolism (RIETE registry), fatal PE occurred in 12% of pa-
tients presenting with massive PE and in 3% of patients with non-
massive PE (Laporte 2008). Therefore, most patients with acute
non-massive PE at presentation have better prognosis and, as in
patients with DVT, it is possible that treatment in a substantial
proportion of these individuals can be safely managed completely,
or at least partially (early discharge), at home (Othieno 2018; Segal
2007). Although not based on high-quality evidence, two retro-
spective cohort studies, Erkens 2010 and Kovacs 2010, showed
that at least 50% of patients presenting with symptomatic PE can
be treated safely as outpatients.
The treatment of acute PE in the outpatient setting, for carefully
selected patients, has been allowed and studied in Europe and
Canada more than in the US. In some hospitals in Canada, about
50% of people with acute PE are managed entirely as outpatients
(Baglin 2010; Kovacs 2010). Conversely, based on the report of
the Multicenter Emergency Medicine Pulmonary Embolism in
the Real World Registry (EMPEROR) (Pollack 2011), in the US
only 1.1% of people attending the emergency department were
discharged home without hospitalisation. Several factors might
be related to this geographic discrepancy, such as issues of health
insurance compensation andmalpractice litigation (Vinson 2012).
The 2014 European Society of Cardiology (ESC) guidelines sug-
gested considering early discharge and outpatient management for
patients judged as low-risk PE (Konstantinides 2014). Neverthe-
less, due to insufficient evidence there is no clear recommendation
of appropriate criteria between Pulmonary Embolism Severity In-
dex (PESI) and Hestia for safe setting of treatment.
The 2018 guideline from the British Thoracic Society (Howard
2018) recommended that patients with confirmed PE should be
risk-stratified using a validated clinical risk score. Patients in PESI
class I/II, sPESI class 0, or those meeting theHestia criteria should
be considered for outpatient management of PE.
Two recently published prospective studies in the US, which used
the PESI to identify patients eligible for outpatient management,
have shown outpatient management to be safe and effective in
treatment of PE in selected low-risk patients with PE (Bledsoe
2018; Vinson 2018). Vinson 2018 employed a more flexible use
of the prediction score in which the PESI class was not strictly
tied to a site-of-care disposition. Rather, the risk class was used to
inform clinical judgement, not direct it. This more flexible use of
the PESI is endorsed by the American College of Chest Physicians
in their recent PE guideline (Kearon 2016).
In this 2018 Cochrane Review, we included only two randomised
controlled trials that compared outpatient management with in-
patient management of acute PE (Aujesky 2011; Peacock 2018).
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Aujesky 2011 used the PESI, a validated risk-stratification instru-
ment, to select low-risk patients who were eligible for outpatient
treatment. These results suggest feasible perspective on the safety
of PE management in an outpatient setting. Peacock 2018 re-
ported preliminary results using the Hestia criteria to select low-
risk PE patients who can be safely and effectively managed as
outpatients with rivaroxaban. The results between outpatient ver-
sus inpatient groups were similar for mortality, thromboembolic
events and haemorrhagic complications were very low and not dif-
ferent between groups. No clear differences were detected between
the outpatient and inpatient groups for the outcomes of mortality,
bleeding, recurrent PE and patient satisfaction. Seemingly both
methods for selection of low-risk PE patients selection (PESI and
Hestia) can be applied with acceptable outcomes. However, a sci-
entific comparison of the two methods in which patients were
randomised to either PESI or Hestia criteria is currently ongoing
(HOME Study).
Further large, randomised studies are required to provide informa-
tion on the selection of low-risk PE patients for outpatient man-
agement. It is currently unclear whether the PESI or the Hestia
criteria is more accurate to identify suitable outpatients, whether
troponin levels have to be considered for safe selection of these
patients, or whether imaging such as echocardiogram and com-
pression ultrasonography of the leg veins are also necessary.
Summary of main results
This review examined the safety and efficacy of outpatient ver-
sus inpatient treatment in low-risk patients with acute PE. We
included two RCTs, with 451 participants, that reported our
primary outcomes. In Aujesky 2011, inpatients and outpatients
were treated with same treatment regimens (enoxaparin 1 mg/kg
twice daily); and in Peacock 2018, inpatients and outpatients were
treated with different treatment regimens (rivaroxaban 15 mg ver-
sus local standard-of-care). No deaths occurred in Peacock 2018,
and two deaths occurred in Aujesky 2011, one in each group. For
short- and long-term mortality, major and minor bleeding, and
recurrent PE there was no clear effect of intervention; there was
imprecision in the results (the numbers of events were very small,
the confidence intervals were wide and included treatment effects
in both directions, and the quality of the evidence was low). See
Summary of findings for themain comparison. There was no clear
evidence to support a difference between the two interventions
regarding patient satisfaction: 92% and 60% of outpatients, and
95% and 63% of inpatients, were very satisfied or satisfied with
the medical care received (Aujesky 2011 and Peacock 2018, re-
spectively). Adverse effects such as haemodynamic instability and
compliance were not assessed by the included studies
Overall completeness and applicability of
evidence
Because of our comprehensive search strategy and contact with ex-
perts in the field, we are confident that we have identified all RCTs
and quasi-RCTs comparing outpatient versus inpatient treatment
for acute PE. This review addresses the non-inferiority hypothesis
that outpatient treatment presents the same benefits as inpatient
treatment for acute PE. Home treatment can improve health-re-
lated quality of life, reduce hospitalisation rates and costs, although
home treatment will incur some health service costs. A key point
from this clinical question is to appropriately select people who are
at low risk to avoid unnecessary risks. More studies are needed to
assess the accuracy of the PESI for identifying a population of low-
risk patients who can be safely and effectively treated without hos-
pitalisation.The PESI, as used byAujesky 2011, consists of 11 rou-
tinely available clinical parameters based on signs and symptoms,
and stratifies patients into five risk classes (I to V) with increasing
risk of short-termmortality (Appendix 2). The validation study of
PESI performed by Aujesky 2007 identified low-risk patients who
are potential candidates for outpatient treatment, with very low
rates of 90-day all-cause mortality (1% or less). Peacock 2018 used
the Hestia criteria (see Appendix 4), which consist of 11 practical
clinical exclusion rules to select patients for outpatient treatment.
The Hestia criteria were later validated in 550 patients by com-
bining the cutoff NT-proBNP levels for outpatient treatment as
500 ng/L (den Exter 2016b). Although in Peacock 2018, the in-
patients and outpatients had different treatment regimens, local
standard-of-care also involved rivaroxaban. Regardless of the dif-
ferent treatment regimes between groups, there was no difference
in results. Neither study reported on all our predefined outcomes,
such as haemodynamic instability, and compliance. We excluded
one RCT from this review because it used a different definition
for outpatients (early discharge was considered as discharge after
three or five days of admission (Otero 2010), compared with less
than 36 hours (Aujesky 2011; Peacock 2018). In addition, Otero
2010 used a non-validated clinical prognostic model to identify
low-risk patients.
Quality of the evidence
The overall quality of the evidence for the primary outcomes of
short- and long-term mortality was low (Summary of findings for
the main comparison). We downgraded our assessments of the
quality of evidence due to the small number of participants and
events, and imprecision. In addition, we were unable to discount
publication bias (Guyatt 2008). It is therefore difficult to draw
robust conclusions on the basis of the available evidence.
Potential biases in the review process
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One area of potential bias in this review is the weakness of statis-
tical power because of the lack of included studies. Although we
performed a well-designed search strategy to identify all potential
studies, we found only two RCTs that met the eligibility criteria,
which makes our findings uncertain.
In the Peacock 2018 trial the outpatient group received rivarox-
aban, and the inpatient group received standard of care (treat-
ment based on local institutional protocols, which may include
an admission, a parenteral anticoagulant and an oral vitamin K
antagonist, or any of the NOACs). This is different from Aujesky
2011, which had similar pharmacological treatments in the in-
patient and outpatient treatment arms. We decided to include
Peacock 2018 because in the inpatient group 50.8% of patients
received rivaroxaban, and the results of the primary outcomes of
Aujesky 2011 and Peacock 2018 were quite similar (low number
of events). We recognise the importance and methodologic rigor
of Aujesky 2011, however, the trial by Peacock and colleagues ap-
pears to be more pragmatic, therefore we considered it important
to include Peacock 2018 and to pool the data. In order to high-
light any potential differences, we performed a subgroup analysis
(inpatients and outpatients with same treatment regimens versus
inpatients and outpatients treated with different treatment regi-
mens). Peacock 2018 used the Hestia criteria to classify patients,
and we therefore considered that most patients were symptomatic.
Agreements and disagreements with other
studies or reviews
We found one systematic review that selected observational stud-
ies, including prospective cohort studies that described the out-
come of people with PE treated entirely as outpatients (Vinson
2012). The review examined the results of exclusive ambulatory
management for people with acute symptomatic PE.However, the
authors only considered an observational period of less than 24
hours, that is, the review did not consider inpatient stay followed
by early discharge. The review also indicated that both treatments
had similar effectiveness. Hence, Vinson 2012 recommended that
patients with low risk of adverse clinical outcomes (e.g. mortality,
recurrence and bleeding) are treated at home due to the advantages
of low cost, avoidance of hospital infections, and high levels of
patient satisfaction (Vinson 2012).
Squizzato and colleagues also conducted a systematic review that
evaluated the effects of outpatient treatment for PE (Squizzato
2009). All of the included studies were observational studies and
the authors concluded that patients might be safely treated at
home. The authors recommended further studies to confirm or
refute these findings.
Three systematic reviews included observational studies and RCTs
(including Aujesky 2011 and Otero 2010, which are included
and excluded in this review respectively). The reviews evaluated
whether outpatient treatment and early discharge were as safe as
conventional inpatient treatment in people with acute PE (Piran
2012; Piran 2013;Zondag 2012). Although heterogeneous criteria
were used for the selection of participants, the results showed that
in a carefully selected group classified as low-risk patients, both
treatments presented similar safety; this is in agreement with the
conclusions of this systematic review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review included two published randomised controlled tri-
als comparing outpatient and inpatient treatment for low-risk pa-
tients with acute pulmonary embolism. The evidence was of low
quality, and did not show any difference between the treatment
groups in overall mortality, bleeding and recurrence of pulmonary
embolism. Further well-conducted research is required before in-
formed practice decisions can be made.
Implications for research
This review highlights the need for further research into the appro-
priate setting of treatment for acute pulmonary embolism. Future
trials need to be adequately powered and should have standardised
outcome measures, such as mortality, hospitalisation rates, health-
related quality of life, and costs.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aujesky 2011
Methods Design: international, open-label, randomised, non-inferiority trial
Multicentre study: 19 EDs in Switzerland, France, Belgium and the US
Period: February 2007 to June 2010.
Sample size: justified (160 participants per treatment group would provide 80% power
to detect a non-inferiority margin of 4% using a 1-sided α of 0.05, assuming a 5% drop-
out rate)
Follow-up: 90 days after randomisation.
Participants 344 eligible participants randomised, but only 339 included in primary analysis; 337
completed follow-up and 317 were included in per-protocol analysis. In the outpatient
group (171 participants): 84 men, 87 women, mean age 47 years; inpatient group (168
participants): 85 men, 83 women, mean age 49 years
Inclusion criteria: aged ≥ 18 years with acute, symptomatic and objectively verified PE
who were at low risk of death based on PESI (risk classes I or II)
Exclusion criteria: arterial hypoxaemia, SBP < 100 mmHg, chest pain necessitating
parenteral opioids, active bleeding, high risk of bleeding, gastrointestinal bleeding, severe
renal failure, extreme obesity, history of HIT or allergy to heparins, therapeutic oral
anticoagulation at the time of diagnosis of PE, pregnancy, diagnosis of PE > 23 hours
before the time of screening
Interventions Outpatient (172 participants): subcutaneous enoxaparin 1 mg/kg twice daily and dis-
charged from the EDwithin 24 hours of randomisation. If self injection was not possible,
a study nurse either taught a caregiver to give the enoxaparin or arranged administration
by a visiting nurse
Inpatient (172 participants): subcutaneous enoxaparin 1mg/kg twice daily and admitted
to hospital
All participants also received vitamin K antagonist therapy.
Outcomes Primary outcome: recurrence of symptomatic confirmed VTE defined as recurrent PE
or new or recurrent DVT within 90 days of randomisation
Secondary outcomes: overall satisfaction, major bleeding within 14 and 90 days of ran-
domisation, all-cause mortality within 90 days
Notes Diagnostic criteria for recurrent PEwere a new intraluminal filling defect on spiral CT or
pulmonary angiography or a new perfusion defect of a lung segment with corresponding
normal ventilation by lung scan or confirmation of a new PE on autopsy.
Diagnostic criteria for DVT were the non-compressibility of a new venous segment or a
substantial increase (≥ 4mm) in the diameter of the thrombus during full compression in
a previously abnormal segment on ultrasonography, or a new intraluminal filling defect
on contrast venography
Overall satisfaction was assessed by a non-validated 5-point Likert scale questionnaire.
Participants completed this questionnaire by telephone 14 days after randomisation
Major bleeding was defined as fatal bleeding, bleeding at critical sites (i.e. intracranial,
intraspinal, intraocular, retroperitoneal, intra-articular, pericardial or intramuscular with
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Aujesky 2011 (Continued)
compartment syndrome), or bleeding with a reduction of haemoglobin of ≥ 20 g/L or
resulting in transfusion of ≥ 2 units of packed red cells
Authors of the study declared they received grants, honoraria, consultancy fees, and
payments from the pharmaceutical industry which sponsored the study. However, both
regimens (outpatient or inpatient) patients received the same treatment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The eligible patients were allocated to out-
patient treatment or inpatient treatment
groups in a one-to-one ratio with a ran-
domised block design generated from a
password protected computer web page
Allocation concealment (selection bias) Low risk The patients were stratified by site and us-
ing small fixed block sizes (2 or 4)
Quote: “To balance recruitment in time
and preclude enrolment bias, the blocks
varied randomly from two to four patients”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Although the paper says that the analysers
were unmasked to treatment group assign-
ment, there was a committee unaware of
treatment assignment which confirmed all
outcomes
Quote: “A committee of three clinical ex-
perts from the University Hospital of Lau-
sanne (Switzerland) who were unaware of
treatment assignment confirmed all out-
comes and classified the cause of all deaths
as definitely due to pulmonary embolism,
possibly due to pulmonary embolism (e.g.,
sudden death without obvious cause), due
to major bleeding, or due to another cause.
”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk < 20% in each group: outpatient group had
2 participants who did not complete fol-
low-up and inpatient group had 5 partici-
pantswhodidnot complete follow-up.The
study authors were unable to confirm how
many were alive
Selective reporting (reporting bias) Low risk There is no evidence of selective reporting.
25Outpatient versus inpatient treatment for acute pulmonary embolism (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Other bias Low risk We did not find aspects of methodology
that might be been influenced by vested
interests and which may lead directly to a
risk of bias
Peacock 2018
Methods Design: international, open-label, randomised, parallel group, multicentre
Multicentre study: 35 sites in the US.
Sample size: 114.
Follow-up: 90 days after randomisation.
Participants Inclusion criteria: adult patients (age ≥ 18 years) with objectively confirmed PE (with
or without symptomatic DVT) who are deemed to be at low risk for recurrent VTE,
major bleeding, or all-cause mortality based on Hestia criteria, and a life expectancy of
at least 6 months. The authors adapted the Hestia criteria by removing the 24-hour time
markers
Exclusion criteria: women of child-bearing age with no use of a highly effective birth con-
trol method, patients with any Hestia criteria present, any concomitant contraindicated
medications, and individuals with contraindications to anticoagulant therapy, allergies
to rivaroxaban, or with barriers to treatment adherence or follow-up
Interventions Intervention (51): outpatient treatment with rivaroxaban 15 mg orally twice daily for
the first 21 days followed by 20 mg orally once daily for approximately 69 days for a
total treatment duration of 90 days
Comparison (63): local standard-of-care, participants received local standard-of-care
according to local protocol and defined by the medical team caring for the participant,
which typically involves bridging therapy and hospitalisation, but also included any of
the NOACs
Outcomes • Mean duration of hospitalisation expressed in hours for venous thromboembolic
or bleeding events, in the 30 days after randomisation
• Major bleeding based on the International Society on Thrombosis and
Haemostasis (ISTH) within 90 days
• Percentage of participants with new/recurrence of VTE, or VTE-related death,
within 7, 14, 30, or 90 days from randomisation
• Percentage of participants with number of unplanned hospital visits or physician
office for VTE symptoms and/or bleeding (up to 7, 14, 30 and 90 days)
• Mean combined duration of initial and subsequent ED hospitalisation for any
reason (up to 30 and 90 days)
• Percentage of participants satisfied using site-of-care satisfaction questionnaire
(day 7) and by ACTS (day 90)
• Clinically relevant non major bleeding, based on ISTH definitions
• Total, all-cause mortality
• Total, serious adverse events
• Costs
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Notes Sponsored by a pharmaceutical industry (Janssen Pharmaceuticals, Raritan, NJ)
The authors used the Hestia criteria to classify patients, therefore we considered that
most patients were symptomatic
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk They used an interactive web system.
Quote: “After obtaining written informed
consent, patients were randomly assigned
in a 1:1 ratio to ED discharge on open-la-
bel rivaroxaban or standard care (as deter-
mined by the attending physician) by an
interactive Web system within 12 hours of
diagnosis.”
Allocation concealment (selection bias) Low risk They used an interactive web system.
Quote: “After obtaining written informed
consent, patients were randomly assigned
in a 1:1 ratio to ED discharge on open-la-
bel rivaroxaban or standard care (as deter-
mined by the attending physician) by an
interactive Web system within 12 hours of
diagnosis.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The analysers were masked to treatment
group assignment.
Quote: “Principal investigators and out-
come adjudicators were masked to group
assignment”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Less than 20% of dropouts and with-
drawals (7 participants in the outpatient
group and 8 participants in the inpatient
group), however the authors did not per-
form intention-to-treat analysis. All out-
patients completed the study and authors
could confirm that all of them were alive,
however in inpatient group they could not
confirm this for two patients
Selective reporting (reporting bias) Low risk There is no evidence of selective reporting.
Other bias Low risk We did not find aspects of methodology
that might be been influenced by vested in-
terests and which may lead directly to a risk
of bias.However, comparisonof two sites of
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Peacock 2018 (Continued)
care (inpatient versus outpatient) was im-
balanced by different pharmacotherapy be-
tween the arms: the outpatient group re-
ceived 15 mg oral rivaroxaban twice daily
for the first 21 days, followed by 20 mg oral
rivaroxaban once daily for approximately
69 days for a total treatment duration of 90
days. The inpatient comparison group re-
ceived local standard-of-care, according to
local protocol and defined by the medical
team caring for the participant, which typ-
ically involved intravenous UFH or subcu-
taneous LMWH and hospitalisation, but
also included any of the NOACs (75% of
all patients were initially treated with un-
fractionated or low-molecular-weight hep-
arin but ultimately received NOACs, most
commonly rivaroxaban (51%) or apixaban
(25%))
ACTS: anti-clot treatment scale
CT: computed tomography
DVT: deep vein thrombosis
ED: emergency department
HIT: heparin-induced thrombocytopenia
ISTH: International Society on Thrombosis and Haemostasis
LMWH: low molecular weight heparin
NOACs: non-vitamin K antagonist oral anticoagulants
PE: pulmonary embolism
PESI: Pulmonary Embolism Severity Index
SBP: systolic blood pressure
UFH: unfractionated heparin
VTE: venous thromboembolism
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
den Exter 2016 Patients were randomised to either outpatient treatment or to management based on NT-pro BNP levels, and not
to either home or inpatient management
HOME Study Patients were randomised to either Hestia or PESI management, and non-randomised to either inpatient or
outpatient treatment
Kovacs 2003 RCT which evaluated different doses of warfarin in outpatients
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Otero 2010 RCT which evaluated 3 to 5 days in the hospital as ’outpatients’
Zondag 2011 Cohort study
NT-pro BNP: N-terminal pro-brain natriuretic peptide
PESI: pulmonary embolism severity index
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Outpatient versus inpatient treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Short-term all-cause mortality 2 451 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.98]
1.1 Inpatients and outpatients
with same treatment regimens
1 339 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.98]
1.2 Inpatients and outpatients
treated with different treatment
regimens
1 112 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Long-term all-cause mortality 2 451 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.06, 15.58]
2.1 Inpatients and outpatients
with same treatment regimens
1 339 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.06, 15.58]
2.2 Inpatients and outpatients
treated with different treatment
regimens
1 112 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Major bleeding within 14 days 2 445 Risk Ratio (M-H, Fixed, 95% CI) 4.91 [0.24, 101.57]
3.1 Inpatients and outpatients
with same treatment regimens
1 339 Risk Ratio (M-H, Fixed, 95% CI) 4.91 [0.24, 101.57]
3.2 Inpatients and outpatients
treated with different treatment
regimens
1 106 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Major bleeding within 90 days 2 445 Risk Ratio (M-H, Fixed, 95% CI) 6.88 [0.36, 132.14]
4.1 Inpatients and outpatients
with same treatment regimens
1 339 Risk Ratio (M-H, Fixed, 95% CI) 6.88 [0.36, 132.14]
4.2 Inpatients and outpatients
treated with different treatment
regimens
1 106 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Minor bleeding 1 106 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.07, 16.79]
6 Recurrent pulmonary embolism
within 90 days
2 445 Risk Ratio (M-H, Fixed, 95% CI) 2.95 [0.12, 71.85]
6.1 Inpatients and outpatients
with same treatment regimens
1 339 Risk Ratio (M-H, Fixed, 95% CI) 2.95 [0.12, 71.85]
6.2 Inpatients and outpatients
treated with different treatment
regimens
1 106 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Satisfaction questionnaire 2 444 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.90, 1.04]
7.1 Inpatients and outpatients
treated with same treatment
regimens
1 337 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.92, 1.03]
7.2 Inpatients and outpatients
with different treatment
regimens
1 107 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.71, 1.30]
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Analysis 1.1. Comparison 1 Outpatient versus inpatient treatment, Outcome 1 Short-term all-cause
mortality.
Review: Outpatient versus inpatient treatment for acute pulmonary embolism
Comparison: 1 Outpatient versus inpatient treatment
Outcome: 1 Short-term all-cause mortality
Study or subgroup Outpatient Inpatient Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Inpatients and outpatients with same treatment regimens
Aujesky 2011 0/171 1/168 100.0 % 0.33 [ 0.01, 7.98 ]
Subtotal (95% CI) 171 168 100.0 % 0.33 [ 0.01, 7.98 ]
Total events: 0 (Outpatient), 1 (Inpatient)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
2 Inpatients and outpatients treated with different treatment regimens
Peacock 2018 0/51 0/61 Not estimable
Subtotal (95% CI) 51 61 Not estimable
Total events: 0 (Outpatient), 0 (Inpatient)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 222 229 100.0 % 0.33 [ 0.01, 7.98 ]
Total events: 0 (Outpatient), 1 (Inpatient)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Outpatient Favours Inpatient
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Analysis 1.2. Comparison 1 Outpatient versus inpatient treatment, Outcome 2 Long-term all-cause
mortality.
Review: Outpatient versus inpatient treatment for acute pulmonary embolism
Comparison: 1 Outpatient versus inpatient treatment
Outcome: 2 Long-term all-cause mortality
Study or subgroup Outpatient Inpatient Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Inpatients and outpatients with same treatment regimens
Aujesky 2011 1/171 1/168 100.0 % 0.98 [ 0.06, 15.58 ]
Subtotal (95% CI) 171 168 100.0 % 0.98 [ 0.06, 15.58 ]
Total events: 1 (Outpatient), 1 (Inpatient)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
2 Inpatients and outpatients treated with different treatment regimens
Peacock 2018 0/51 0/61 Not estimable
Subtotal (95% CI) 51 61 Not estimable
Total events: 0 (Outpatient), 0 (Inpatient)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 222 229 100.0 % 0.98 [ 0.06, 15.58 ]
Total events: 1 (Outpatient), 1 (Inpatient)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Outpatient Favours Inpatient
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Analysis 1.3. Comparison 1 Outpatient versus inpatient treatment, Outcome 3 Major bleeding within 14
days.
Review: Outpatient versus inpatient treatment for acute pulmonary embolism
Comparison: 1 Outpatient versus inpatient treatment
Outcome: 3 Major bleeding within 14 days
Study or subgroup Outpatient Inpatient Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Inpatients and outpatients with same treatment regimens
Aujesky 2011 2/171 0/168 100.0 % 4.91 [ 0.24, 101.57 ]
Subtotal (95% CI) 171 168 100.0 % 4.91 [ 0.24, 101.57 ]
Total events: 2 (Outpatient), 0 (Inpatient)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
2 Inpatients and outpatients treated with different treatment regimens
Peacock 2018 0/51 0/55 Not estimable
Subtotal (95% CI) 51 55 Not estimable
Total events: 0 (Outpatient), 0 (Inpatient)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 222 223 100.0 % 4.91 [ 0.24, 101.57 ]
Total events: 2 (Outpatient), 0 (Inpatient)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Outpatient Favours Inpatient
33Outpatient versus inpatient treatment for acute pulmonary embolism (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.4. Comparison 1 Outpatient versus inpatient treatment, Outcome 4 Major bleeding within 90
days.
Review: Outpatient versus inpatient treatment for acute pulmonary embolism
Comparison: 1 Outpatient versus inpatient treatment
Outcome: 4 Major bleeding within 90 days
Study or subgroup Outpatient Inpatient Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Inpatients and outpatients with same treatment regimens
Aujesky 2011 3/171 0/168 100.0 % 6.88 [ 0.36, 132.14 ]
Subtotal (95% CI) 171 168 100.0 % 6.88 [ 0.36, 132.14 ]
Total events: 3 (Outpatient), 0 (Inpatient)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
2 Inpatients and outpatients treated with different treatment regimens
Peacock 2018 0/51 0/55 Not estimable
Subtotal (95% CI) 51 55 Not estimable
Total events: 0 (Outpatient), 0 (Inpatient)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 222 223 100.0 % 6.88 [ 0.36, 132.14 ]
Total events: 3 (Outpatient), 0 (Inpatient)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
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Analysis 1.5. Comparison 1 Outpatient versus inpatient treatment, Outcome 5 Minor bleeding.
Review: Outpatient versus inpatient treatment for acute pulmonary embolism
Comparison: 1 Outpatient versus inpatient treatment
Outcome: 5 Minor bleeding
Study or subgroup Outpatient Inpatient Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Peacock 2018 1/51 1/55 100.0 % 1.08 [ 0.07, 16.79 ]
Total (95% CI) 51 55 100.0 % 1.08 [ 0.07, 16.79 ]
Total events: 1 (Outpatient), 1 (Inpatient)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
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Analysis 1.6. Comparison 1 Outpatient versus inpatient treatment, Outcome 6 Recurrent pulmonary
embolism within 90 days.
Review: Outpatient versus inpatient treatment for acute pulmonary embolism
Comparison: 1 Outpatient versus inpatient treatment
Outcome: 6 Recurrent pulmonary embolism within 90 days
Study or subgroup Outpatient Inpatient Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Inpatients and outpatients with same treatment regimens
Aujesky 2011 1/171 0/168 100.0 % 2.95 [ 0.12, 71.85 ]
Subtotal (95% CI) 171 168 100.0 % 2.95 [ 0.12, 71.85 ]
Total events: 1 (Outpatient), 0 (Inpatient)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
2 Inpatients and outpatients treated with different treatment regimens
Peacock 2018 0/51 0/55 Not estimable
Subtotal (95% CI) 51 55 Not estimable
Total events: 0 (Outpatient), 0 (Inpatient)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 222 223 100.0 % 2.95 [ 0.12, 71.85 ]
Total events: 1 (Outpatient), 0 (Inpatient)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Outpatient Favours Inpatient
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Analysis 1.7. Comparison 1 Outpatient versus inpatient treatment, Outcome 7 Satisfaction questionnaire.
Review: Outpatient versus inpatient treatment for acute pulmonary embolism
Comparison: 1 Outpatient versus inpatient treatment
Outcome: 7 Satisfaction questionnaire
Study or subgroup Outpatient Inpatient Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Inpatients and outpatients treated with same treatment regimens
Aujesky 2011 156/170 158/167 82.8 % 0.97 [ 0.92, 1.03 ]
Subtotal (95% CI) 170 167 82.8 % 0.97 [ 0.92, 1.03 ]
Total events: 156 (Outpatient), 158 (Inpatient)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
2 Inpatients and outpatients with different treatment regimens
Peacock 2018 29/48 37/59 17.2 % 0.96 [ 0.71, 1.30 ]
Subtotal (95% CI) 48 59 17.2 % 0.96 [ 0.71, 1.30 ]
Total events: 29 (Outpatient), 37 (Inpatient)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Total (95% CI) 218 226 100.0 % 0.97 [ 0.90, 1.04 ]
Total events: 185 (Outpatient), 195 (Inpatient)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
0.5 0.7 1 1.5 2
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A P P E N D I C E S
Appendix 1. Geneva prediction score (GPS)
Predictors Point score
Cancer +2
Heart failure +1
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(Continued)
Previous deep vein thrombosis +1
Systolic blood pressure < 100 mmHg +2
PaO2< 8kPa +1
Deep vein thrombosis shown by ultrasound +1
Total score 0-8
Patients with a total score ≤ 2 were assigned to the low-risk category, and those with a total score ≥ 3 points to the high-risk category
Appendix 2. The Pulmonary Embolism Severity Index (PESI)
Predictors Points assigned
Age, per year Age, in years
Male sex +10
History of cancer +30
History of heart failure +10
History of chronic lung disease +10
Pulse rate ≥ 110/minute +20
Systolic blood pressure < 100 mmHg +30
Respiratory rate ≥ 30/minute* +20
Temperature < 36 °C +20
Altered mental status† +60
Arterial oxygen saturation < 90%* +20
A total point score for a given patient is obtained by summing the patient’s age in years and the points for each applicable predictor.
Points assignments correspond with the following risk classes:≤ 65 class I; 66-85 class II; 86-105 class III; 106-125 class IV and > 125
class V. Patients in risk classes I and II are defined as low-risk.
*Assessed with or without the administration of supplemental oxygen.
†Defined as confusion, disorientation or somnolence.
38Outpatient versus inpatient treatment for acute pulmonary embolism (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 3. The simplified version of the PESI (sPESI)
Variable Points assigned
Age > 80 years 1
History of cancer 1
Chronic cardiopulmonary disease 1
Pulse rate ≥ 110/minute 1
Systolic blood pressure < 100 mmHg 1
Arterial oxygen saturation < 90% 1
A total point score for a given patient is obtained by summing the points. The score corresponds with the following risk classes: 0, low
risk; 1 or more, high risk. Empty cells indicate that the variable was not included
Appendix 4. Hestia criteria
Is the patient haemodynamically unstable? a
Is thrombolysis or embolectomy necessary?
Active bleeding or high risk of bleeding? b
> 24 h of oxygen supply to maintain oxygen saturation > 90%?
Is pulmonary embolism diagnosed during anticoagulant treatment?
Severe pain needing intravenous pain medication for > 24 h?
Medical or social reason for treatment in the hospital for > 24 h (infection, malignancy, no support system)?
Does the patient have a creatinine clearance of < 30 mL/min? c
Does the patient have severe liver impairment? d
Is the patient pregnant?
Does the patient have a documented history of heparin-induced thrombocytopenia?
Hestia rule interpretation: If the answer to one of the questions is yes, in-hospital treatment is recommended (Hestia rule positive). If
the answer to all the questions is no, home treatment is recommended (Hestia rule negative).
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a Include the following criteria, but leave these to the discretion of the clinician: systolic blood pressure < 100 mmHg with heart rate
> 100 beats/min; condition requiring admission to an intensive care unit.
b Gastrointestinal bleeding in the preceding 14 days, recent stroke (< 4 weeks ago), recent operation (< 2 weeks ago), bleeding disorder
or thrombocytopenia (platelet count < 75 x 109/L), uncontrolled hypertension (systolic blood pressure > 180 mmHg or diastolic blood
pressure > 110 mmHg).
c Calculated creatinine clearance according to the Cockroft-Gault formula.
d Left to the discretion of the physician.
Appendix 5. British Thoracic Society exclusion criteria for outpatients management or early
discharge
• Haemodynamic instability (heart rate > 110 beats/min; systolic blood pressure < 100 mmHg; requirement for inotropes and
critical care; requirement for thrombolysis or embolectomy)
• Oxygen saturations < 90% on air
• Active bleeding or risk of major bleeding (eg. recent gastrointestinal bleed or surgery, previous intracranial bleeding,
uncontrolled hypertension)
• On full-dose anticoagulation at the time of the pulmonary embolism
• Severe pain (eg. requiring opiates)
• Other medical comorbidities requiring hospital admission
• Chronic kidney disease stages 4 or 5 (estimated glomerular filtration rate < 30 mL/min) or severe liver disease
• Heparin-induced thrombocytopenia within the last year and where there is no alternative to repeating heparin treatment
• Social reasons which may include inability to return home, inadequate care at home, lack of telephone communication,
concerns over compliance, etc.
Appendix 6. Database searches
Source Search strategy Hits retrieved
CENTRAL via CRSO #1 MESH DESCRIPTOR Thrombosis 1309
#2 MESH DESCRIPTOR Thromboembolism 953
#3 MESH DESCRIPTOR Venous Thromboem-
bolism 311
#4MESHDESCRIPTOR Venous Thrombosis EX-
PLODE ALL TREES 2108
#5 (thrombus* or thrombotic* or thrombolic* or
thromboemboli* or thrombos* or embol*):TI,AB,
KY 21426
#6 MESH DESCRIPTOR Pulmonary Embolism
EXPLODE ALL TREES 781
#7 (PE or DVT or VTE):TI,AB,KY 5796
#8 (((vein* or ven*) near thromb*)):TI,AB,KY 7539
#9 (blood near/3 clot* ):TI,AB,KY 0
#10 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #
7 OR #8 OR #9 25483
#11 MESH DESCRIPTOR Outpatients EX-
PLODE ALL TREES 1066
#12 MESH DESCRIPTOR Inpatients EXPLODE
ALL TREES 782
#13 MESH DESCRIPTOR Patient Care EX-
1759
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(Continued)
PLODE ALL TREES 53193
#14 MESH DESCRIPTOR Ambulatory Care EX-
PLODE ALL TREES 3410
#15 MESH DESCRIPTOR Home Nursing EX-
PLODE ALL TREES 273
#16 MESH DESCRIPTOR Hospitalization EX-
PLODE ALL TREES 11800
#17 MESH DESCRIPTOR Outpatient Clinics,
Hospital EXPLODE ALL TREES 626
#18 in-patient :TI,AB,KY 5836
#19 inpatient :TI,AB,KY 6041
#20 hospitali* :TI,AB,KY 29944
#21 bed-ridden :TI,AB,KY 22
#22 home :TI,AB,KY 22684
#23 out-patient :TI,AB,KY 1341
#24 outpatient :TI,AB,KY 17880
#25 ambulatory* :TI,AB,KY 16079
#26 domicil* :TI,AB,KY 418
#27 #11 OR #12 OR #13 OR #14 OR #15 OR #
16 OR #17 OR #18 OR #19 OR #20 OR #21 OR
#22 OR #23 OR #24 OR #25 OR #26 123614
#28 #10 AND #27 3293
#29 01/01/2014 TO 26/03/2018:CD 408317
#30 #28 AND #29 1759
Clinicaltrials.gov Outpatient OR Outpatients OR Inpatient OR In-
patients OR Patient Care OR Ambulatory Care OR
Home Nursing OROutpatient Clinics | Pulmonary
EmbolismORAcute Pulmonary EmbolismORPul-
monary Thromboembolism | Last update posted
from 01/01/2014 to 03/28/2018
195
ICTRP Search Portal Pulmonary Embolism OR Acute Pulmonary Em-
bolism OR Pulmonary Thromboembolism OR Pul-
monary AND Outpatient OR Outpatients OR In-
patient OR Inpatients OR Patient Care OR Ambu-
latory Care OR Home Nursing OR Hospitalization
OR Outpatient Clinics
73
MEDLINE 1 THROMBOSIS/ 65220
2 THROMBOEMBOLISM/ 22449
3 Venous Thromboembolism/ 8046
4 exp Venous Thrombosis/ 51000
5 (thrombus* or thrombotic* or thrombolic* or
thromboemboli* or thrombos* or embol*).ti,ab.
295531
6 exp Pulmonary Embolism/ 35920
7 (PE or DVT or VTE).ti,ab. 45444
8 ((vein* or ven*) adj thromb*).ti,ab. 60141
653
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(Continued)
9 (blood adj3 clot*).ti,ab. 9925
10 or/1-9 382689
11 exp OUTPATIENTS/ 13278
12 exp Patient Care/ 849726
13 exp Ambulatory Care/ 49708
14 exp Home Nursing/ 9116
15 exp Outpatient Clinics, Hospital/ 16494
16 in-patient.ti,ab. 52003
17 inpatient.ti,ab. 63402
18 bed-ridden.ti,ab. 459
19 exp INPATIENTS/ 17707
20 Home Nursing/ 8361
21 Outpatient Clinics, Hospital/ 15165
22 in-patient.ti,ab. 52003
23 Inpatient*.ti,ab. 88382
24 bed-ridden.ti,ab. 459
25 out-patient.ti,ab. 9890
26 outpatient.ti,ab. 109086
27 ambulatory*.ti,ab. 70535
28 domicil*.ti,ab. 3802
29 or/11-28 1093389
30 randomized controlled trial.pt. 456087
31 controlled clinical trial.pt. 92247
32 randomized.ab. 405922
33 placebo.ab. 187323
34 drug therapy.fs. 2001767
35 randomly.ab. 287027
36 trial.ab. 421562
37 groups.ab. 1775080
38 or/30-37 4163193
39 (2017* or 2018*).ed. 1137739
40 10 and 29 and 38 and 39 653
41 from 40 keep 1-653 653
Embase 1 thrombosis/ 93511
2 thromboembolism/ 49292
3 venous thromboembolism/ 30143
4 exp vein thrombosis/ 94140
5 (thrombus* or thrombotic* or thrombolic* or
thromboemboli* or thrombos* or embol*).ti,ab.
336866
6 (PE or DVT or VTE).ti,ab. 66507
7 ((vein* or ven*) adj3 thromb*).ti,ab. 84338
8 (blood adj3 clot*).ti,ab. 9231
9 or/1-8 465829
10 exp outpatient/ 90993
11 exp patient care/ 616173
12 exp ambulatory care/ 31732
13 exp home care/ 48012
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14 exp outpatient department/ 45341
15 in-patient.ti,ab. 79159
16 inpatient.ti,ab. 93577
17 bed-ridden.ti,ab. 532
18 hospital patient/ 129991
19 exp home care/ 48012
20 exp outpatient department/ 45341
21 in-patient.ti,ab. 79159
22 Inpatient*.ti,ab. 123955
23 bed-ridden.ti,ab. 532
24 out-patient.ti,ab. 12569
25 outpatient.ti,ab. 151131
26 ambulatory*.ti,ab. 73129
27 domicil*.ti,ab. 3148
28 or/10-27 1066126
29 domicil*.ti,ab. 3148
30 controlled clinical trial/ 411625
31 random$.ti,ab. 1147104
32 randomization/ 69127
33 intermethod comparison/ 222434
34 placebo.ti,ab. 219134
35 (compare or compared or comparison).ti. 329390
36 ((evaluated or evaluate or evaluating or assessed
or assess) and (compare or compared or comparing
or comparison)).ab. 1585695
37 (open adj label).ti,ab. 61445
38 ((double or single or doubly or singly) adj (blind
or blinded or blindly)).ti,ab. 155643
39 double blind procedure/ 121111
40 parallel group$1.ti,ab. 19247
41 (crossover or cross over).ti,ab. 71025
42 ((assign$ or match or matched or allocation) adj5
(alternate or group$1 or intervention$1 or patient$1
or subject$1 or participant$1)).ti,ab. 244589
43 (assigned or allocated).ti,ab. 285412
44 (controlled adj7 (study or design or trial)).ti,ab.
256876
45 (volunteer or volunteers).ti,ab. 169739
46 trial.ti. 210016
47 or/29-46 3403612
48 (2017* or 2018*).em. 3130096
CINAHL S41 S39 AND S40 154
S40 EM 2017 OR EM 2018 291,195
S39 S25 AND S38 2,520
S38 S26 OR S27 OR S28 OR S29 OR S30 OR S31
OR S32 OR S33 OR S34 OR S35 OR S36 OR S37
336,569
S37 (MH “Random Assignment”) 37,362
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S36 (MH “Single-Blind Studies”) or (MH “Double-
Blind Studies”) or (MH “Triple-Blind Studies”) 32,
494
S35 (MH “Crossover Design”) 11,043
S34 (MH “Factorial Design”) 911
S33 (MH “Placebos”) 8,331
S32 (MH “Clinical Trials”) 92,961
S31 TX “multi-centre study” OR “multi-center
study” OR “multicentre study” OR “multicenter
study” OR “multi-site study” (4,394
S30 TX crossover OR “cross-over” 14,345
S29 AB placebo* 27,892
S28 TX random* 215,310
S27 TX trial* 246,180
S26 TX “latin square” 141
S25 S10 AND S24 12,647
S24 S11 OR S12 OR S13 OR S14 OR S15 OR S16
OR S17 OR S18 OR S19 OR S20 OR S21 OR S22
OR S23 700,842
S23 TX “out-patient” 1,421
S22 TX “in-patient” 600,886
S21 TX domicil* 1,108
S20 TX ambulatory* 34,561
S19 TX outpatient 65,392
S18 TX bed-ridden 41
S17 TX inpatient 86,288
S16 (MH “Ambulatory Care Facilities”) 4,047
S15 (MH “Home Nursing”) 2,937
S14 (MH “Ambulatory Care”) 7,125
S13 (MH “Patient Care”) 16,853
S12 (MH “Inpatients”) 65,637
S11 (MH “Outpatients”) 36,503
S10 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7
OR S8 OR S9 45,072
S9 TX blood n3 clot* 890
S8 TX ((vein* or ven*) n2 thromb*) 11,142
S7 TX PE or DVT or VTE 11,729
S6 (MH “Pulmonary Embolism”) 4,685
S5 TX thrombus* or thrombotic* or thrombolic* or
thromboemboli* or thrombos* or embol* 35,636
S4 (MH “Venous Thrombosis+”) 6,338
S3 (MH “Venous Thromboembolism”) 3,034
S2 (MH “Thromboembolism”) 3,207
S1 (MH “Thrombosis”) 4,590
AMED 1 THROMBOSIS/ 198
2 THROMBOEMBOLISM/ 72
3 Venous Thromboembolism/ 0
4 exp Venous Thrombosis/ 0
5 (thrombus* or thrombotic* or thrombolic* or
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thromboemboli* or thrombos* or embol*).ti,ab. 638
6 exp Pulmonary Embolism/ 53
7 (PE or DVT or VTE).ti,ab. 243
8 ((vein* or ven*) adj thromb*).ti,ab. 308
9 (blood adj3 clot*).ti,ab. 34
10 or/1-9 863
11 exp OUTPATIENTS/ 317
12 exp Patient Care/ 5736
13 exp Ambulatory Care/ 414
14 exp Home Nursing/ 615
15 exp Outpatient Clinics, Hospital/ 87
16 in-patient.ti,ab. 23780
17 inpatient.ti,ab. 2899
18 bed-ridden.ti,ab. 7
19 exp INPATIENTS/ 414
20 Home Nursing/ 515
21 Outpatient Clinics, Hospital/ 86
22 in-patient.ti,ab. 23780
23 Inpatient*.ti,ab. 3501
24 bed-ridden.ti,ab. 7
25 out-patient.ti,ab. 23780
26 outpatient.ti,ab. 2926
27 ambulatory*.ti,ab. 1186
28 domicil*.ti,ab. 119
29 or/11-28 33684
30 10 and 29 246
31 exp CLINICAL TRIALS/ 3711
32 RANDOM ALLOCATION/ 314
33 DOUBLE BLIND METHOD/ 643
34 Clinical trial.pt. 1205
35 (clinic* adj trial*).tw. 5324
36 ((singl* or doubl* or trebl* or tripl*) adj (blind*
or mask*)).tw. 2782
37 PLACEBOS/ 583
38 placebo*.tw. 3070
39 random*.tw. 17240
40 PROSPECTIVE STUDIES/ 1047
41 or/31-40 22174
42 30 and 41 28
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F E E D B A C K
Aujesky, 2 December 2014
Summary
The systematic review on outpatient versus inpatient treatment of pulmonary embolism (PE) by Yoo, Queluz, and El Dib published
in the Cochrane Library in November 14, 2014 noted our randomized non-inferiority trial1 as the sole study deemed worthy to be
included in the systematic review. However, the review authors declare in the abstract that our study quality is “very low” because
“blinding of the outcome assessors was not reported”. Furthermore, the authors say in the summary of findings that “it is possible to
blind for this clinical question”. We disagree with these statements. While our data analysts knew treatment assignment, we blinded the
outcome assessors to treatment arm, as explicitly described in the published manuscript. Yoo, et al. call for “well-conducted randomized
controlled trials (where people are allocated at random to one of two or more treatments groups, one of which is a control (dummy!)
treatment)”, we cannot imagine a design differing from ours that would allow participants and study personnel to be blinded for home
versus hospital care. Finally, contrary to the assertion in this review, we never described our trial as double-blind placebo-controlled
clinical trial but as “an international, open-label, randomised, non-inferiority trial.” We hope these variances from the trial design will
be incorporated into the Cochrane review.
The challenge of doing a systematic review that analyzes data on a topic where a singular experimental design exists is laid bare in this
effort; perhaps this topic - in contrast to the care of deep venous thrombosis absent PE - is not ready for such an analysis. We also look
forward to more data that will help guide implementation of care options outside the hospital for those with acute PE.
Reference:
1Aujesky D, Roy PM, Verschuren F, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an
international, open-label, randomised, non-inferiority trial. Lancet. 2011;378:41-8.
Reply
We thank you very much for your comments on this review. Please see below our responses:
1. We reviewed the domain related to blinding of personnel and participants and we decided to withdraw this domain from the risk of
bias assessment because it is not applicable for this clinical question due to the nature of the interventions.
2. As per your paper on page 42 you quoted that “Data analysers were unmasked to treatment group assignment” but you did not
specify that the data analyser was the same as the outcome assessor. As we used the risk of bias assessment according to Higgins 2011,
we judged this domain as high risk of bias. However, as per your clarification we have changed this domain to low risk of bias.
3. As per your comment related to “very low quality evidence”, this was classified according to the GRADE principles (Guyatt 2008)
which recognize the precision of the confidence interval, sample size, publication bias and heterogeneity. However, most of these items
were not addressed due to the fact there was only one included study. We have reclassified to ’low quality of evidence’ following the
reclassification of the risk of detection bias.
4.We revised the description of the trial from ’multicenter randomised double-blind placebo-controlled clinical trial’ to ’an international,
open-label, randomised, non-inferiority trial’.
Thank you very much.
Contributors
Feedback: Drahomir Aujesky MD, MSc and Donald M. Yealy MD
Reply: Dr Hugo Yoo, Dr Thais Queluz, and Regina El Dib, PhD
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WH A T ’ S N E W
Date Event Description
26 March 2018 New citation required but conclusions have not changed A new search was run, which resulted in one new in-
cluded study and two new excluded studies. New au-
thors have joined the review team. There are no changes
to the conclusions
26 March 2018 New search has been performed A new search was run, which resulted in one new in-
cluded study and two new excluded studies
H I S T O R Y
Protocol first published: Issue 8, 2012
Review first published: Issue 11, 2014
Date Event Description
4 February 2015 Feedback has been incorporated The review authors have responded to the feedback submitted December
2014 and revised their review accordingly
2 December 2014 Feedback has been incorporated Feedback has been submitted for this review. The review authors have been
invited to respond to the feedback
C O N T R I B U T I O N S O F A U T H O R S
Conceiving the review: HHBY
Co-ordinating the review: CB
Undertaking manual searches: HHBY
Screening search results: HHBY, VSNN and PJFVB
Organising retrieval of papers: HHBY
Screening retrieved papers against inclusion criteria: HHBY, VSNN and PJFVB
Appraising quality of papers: VSNN and PJFVB
Abstracting data from papers: HHBY, VSNN and PJFVB
Writing to authors of papers for additional information: HHBY
Obtaining additional data about papers: HHBY
Obtaining and screening data on unpublished studies: HHBY
Data management for the review: HHBY, VSNN and PJFVB
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Data entry: VSNN and PJFVB
Statistical data analysis: VSNN
Double entry of data: (data entered by person one: HHBY; data entered by person two: VSNN)
Interpretation of data: HHBY, VSNN and PJFVB
Statistical inferences: HHBY, VSNN and PJFVB
Writing the review: HHBY, VSNN, PJFVB and CB
Guarantor for the review: HHBY
Person responsible for reading and checking review before submission: HHBY, VSNN, PJFVB and CB
D E C L A R A T I O N S O F I N T E R E S T
HHBY: none known.
VSNN: received travel and meeting expenses from Norvartis for attending the annual meetings of the Endocrine Society between 2009
and 2013.
PJFVB: none known.
CB: none known.
S O U R C E S O F S U P P O R T
Internal sources
• São Paulo State University-UNESP, Brazil.
RENOVE-0108/008/13-PROPe/CDC
External sources
• Chief Scientist Office, Scottish Government Health Directorates, The Scottish Government, UK.
The Cochrane Vascular editorial base is supported by the Chief Scientist Office.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
2018 review version
In Types of participants, the measurement tools that aim to classify mortality risk rate was expanded to be as inclusive as possible. The
age of participants was amended from > 18 years to ≥ 18 years.
In Types of outcome measures, we amended the length of short-term mortality from 30 days to 7 to 10 days to reflect more accurately
the short-term nature.
In Subgroup analysis and investigation of heterogeneity we included:
• inpatients and outpatients with same treatment regimens versus inpatients and outpatients treated with different treatment
regimens.
In the single study included in the previous version of this review, both inpatients and outpatients received the same treatment regimen.
For this update, the inpatient and outpatient groups in a new included study received different treatment regimens. We have added
this subgroup analysis to assess any potential effects.
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2014 review version
The objective was rephrased according to Cochrane guidelines.
In Types of participants, the definition of acute pulmonary embolism was amended to be as inclusive as possible.
In Types of interventions, the definition of ’outpatients’ was amended to reflect true cases of outpatients only and avoid confusion with
’early discharge’ and ’outpatients’.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Ambulatory Care; ∗Hospitalization; Acute Disease; Confidence Intervals; Pulmonary Embolism [mortality; ∗therapy]; Randomized
Controlled Trials as Topic
MeSH check words
Adult; Humans
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